

F.No:7-5/2013/EU/WC-050
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road
New Delhi-110002

Dated: 17 JUN 2019

To
M/s.Morepen Laboratories Ltd,
Morepen Village,
Baddi Nalagarh Road, Baddi, Distt.Solan,
Himachal Pradesh, INDIA.

SUB: -Written Confirmation of M/s.Morepen Laboratories Ltd., Morepen Village, Baddi Nalagarh Road, Baddi, Distt-Solan, Himachal Pradesh, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your application submitted to CDSCO, Baddi Zone and the recommendation received from DDC (I), Baddi Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non-Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.

8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of issue	Validity
01	09	17 JUN 2019	Three years from the date of issue

Yours faithfully,



(Dr. S. Eswara Reddy)
Drugs Controller General (India)

ok

sp

07.06.19

for
7.6.19

Wk
07/06/19



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. Morepen Laboratories Ltd,
Morepen Village
Baddi Nalagarh Road, Baddi,
Distt. Solan, Himachal Pradesh, INDIA.

2. Manufacturer's license number: NB/98-05 & B/98-06

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

As per list enclosed as Annexure -01

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7):

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 11th & 12th Mar 2019.

The Written Confirmation remains valid until: Three years from the date of issue.

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: Central Drugs Standard Control Organisation
FDA Bhawan, Kotla Road,
New Delhi- 110 002, India.

Name and function of responsible person: Dr. S. Eswara Reddy,
Drugs Controller General (India).

E-mail: dci@nic.in,
Telephone no.: +91-11-23236965
Fax no.: +91-11-23236973

Signature

Stamp of the authority and date



17 JUN 2019

Handwritten notes and signatures at the bottom of the page, including dates like 07.06.19 and 07.06.19, and a signature.



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. Morepen Laboratories Ltd,
Morepen Village
Baddi Nalagarh Road, Baddi Distt.
Solan, Himachal Pradesh, INDIA.

List of APIs:

S. No.	Active substance (s)	Activity(ies)
1.	Atorvastatin Calcium Trihydrate EP	Manufacturing & Packing
2.	Fexofenadine Hydrochloride USP/EP	Manufacturing & Packing
3.	Loratadine USP/EP	Manufacturing & Packing
4.	Montelukast Sodium USP/EP	Manufacturing & Packing
5.	Rosuvastatin Calcium EP	Manufacturing & Packing
6.	Sitagliptin Phosphate Monohydrate EP	Manufacturing & Packing
7.	Saxagliptin Hydrochloride IH	Manufacturing & Packing
8.	Olmesartan Medoxomil EP	Manufacturing & Packing
9.	Atorvastatin Calcium USP	Manufacturing & Packing

ITEM(S) Nine (09) Only

The Written Confirmation remains valid until: Three years from the date of Issue

Signature

Stamp of the authority and date



17 JUN 2019

07.6.19
7.6.19
07.6.19

